Jonathan L. Isaacsohn

3.1k citations

50 papers · 2.4k indexed · h-index 22

Endocrinology, Diabetes and Metabolism top 2%
- Diabetes, Cardiovascular Risks, and Lipoproteins 16
Surgery top 2%
- Lipoproteins and Cardiovascular Health 36
Cardiology and Cardiovascular Medicine top 5%
Nutrition and Dietetics top 2%
- Fatty Acid Research and Health 5
Biochemistry top 5%
Cancer Research
- Cancer, Lipids, and Metabolism 11
Economics and Econometrics
- Health Systems, Economic Evaluations, Quality of Life 8
- Pharmaceutical Economics and Policy 7
Oncology
- Drug Transport and Resistance Mechanisms 2
Radiology, Nuclear Medicine and Imaging
- Cardiac Imaging and Diagnostics 2

Co-authors: John J.P. Kastelein Harold Bays Christie M. Ballantyne Paresh N. Soni Rene A. Braeckman Evan A. Stein Lawrence Brass C.D. Robinette
Cited by: Endocrinology, Diabetes and Metabolism Surgery Cardiology and Cardiovascular Medicine
Partner nations: United States Switzerland Netherlands

In The Last Decade

Jonathan L. Isaacsohn

48 papers receiving 2.2k citations

Peers

Countries citing papers authored by Jonathan L. Isaacsohn

Since Specialization

Citations

This map shows the geographic impact of Jonathan L. Isaacsohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan L. Isaacsohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan L. Isaacsohn more than expected).

Fields of papers citing papers by Jonathan L. Isaacsohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan L. Isaacsohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan L. Isaacsohn. The network helps show where Jonathan L. Isaacsohn may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jonathan L. Isaacsohn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jonathan L. Isaacsohn Line = papers co-authored together Jonathan L. Isaacsohn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) Christie M. Ballantyne,Harold Bays,John J.P. Kastelein,Evan A. Stein,Jonathan L. Isaacsohn,Rene A. Braeckman,Paresh N. Soni	2012	256
2	Abstract 15071: AMR101 Lowers Triglycerides, Atherogenic Lipoprotein, Phospholipase A2, and High-sensitivity C-reactive Protein Levels in Patients With High Triglycerides and on Background Statin Therapy (the ANCHOR Study) Christie M. Ballantyne,Harold Bays,John J.P. Kastelein,Evan A. Stein,Jonathan L. Isaacsohn,Rene A. Braeckman,Paresh N. Soni	2011	3
3	Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial) Harold Bays,Christie M. Ballantyne,John J.P. Kastelein,Jonathan L. Isaacsohn,Rene A. Braeckman,Paresh N. Soni	2011	275
4	The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: A pooled analysis of double-blind, randomized trials Hallvard Holdaas,Christoph Wanner,C. Abletshauser,Claudio Gimpelewicz,Jonathan L. Isaacsohn	2006	21
5	The Renal Safety Profile of Fluvastatin: Results of a Pooled Analysis Hallvard Holdaas,Christoph Wanner,C. Abletshauser,Claudio Gimpelewicz,Jonathan L. Isaacsohn	2006	0
6	Comparison of Efficacy and Safety of Rosuvastatin Versus Atorvastatin in African-American Patients in a Six-Week Trial Keith C. Ferdinand,Luther T. Clark,Karol E. Watson,Ryan C. Neal,Clinton D. Brown,B. Waine Kong,Boisey O. Barnes,William R. Cox,Franklin J. Zieve,Jonathan L. Isaacsohn,J. Ycas,Philip T. Sager,Alex Gold	2005	56
7	The challenges of conducting clinical endpoint studies Jonathan L. Isaacsohn,Tiffany A. Khodadad,Catherine Soldano-Noble,Jeffrey Vest	2003	1
8	Effects of simvastatin, an HMG‐CoA reductase inhibitor, in patients with hypertriglyceridemia Jonathan L. Isaacsohn,Donald B. Hunninghake,Helmut G. Schrott,Carlos A. Dujovne,Robert H. Knopp,Stuart Weiss,Harold Bays,John R. Crousei,Michael H. Davidson,L.M. Keilson,James M. McKenney,Stanleyg Korenman,Adrians Dobs,Evan A. Stein,Ronald M. Krauss,Darbie Maccubbin,Meeh Yung Cho,D. Plotkin,Yale Mitchel	2003	21
9	Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates ( bezafibrate , fenofibrate , or gemfibrozil ) Michel Farnier,Michele Bortolini,Thomas Salko,Marie-Odile Freudenreich,Jonathan L. Isaacsohn,August J. Troendle,Leonard Gonasun	2003	17
10	The impact of the national cholesterol education program adult treatment panel III guidelines on drug development Jonathan L. Isaacsohn,Donald M. Black,August J. Troendle,David G. Orloff	2002	5
11	Frequency of creatine kinase elevation during treatment with fluvastatin Renée Benghozi,Michele Bortolini,Yan Jia,Jonathan L. Isaacsohn,August J. Troendle,Leonard Gonasun	2002	29
12	Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia Michael H. Davidson,Phillip D. Toth,Stuart Weiss,James M. McKenney,Donald Hunninghake,Jonathan L. Isaacsohn,Joanne M. Donovan,Steven K. Burke	2001	81
13	Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults Jonathan L. Isaacsohn,Miguel A. Zinny,A. Mazzu,John Lettieri,Allen H. Heller	2001	5
14	Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels John J.P. Kastelein,Jonathan L. Isaacsohn,Leiv Ose,Donald B. Hunninghake,Jiří Fröhlich,Michael H. Davidson,Rafik Habib,Carlos A. Dujovne,John R. Crouse,Minzhi Liu,Michael Melino,Laura O’Grady,Michele Mercuri,Yale Mitchel	2000	55
15	Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE)—rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease Jonathan L. Isaacsohn,Michael H. Davidson,Donald B. Hunninghake,Robert Singer,Richard McLain,Donald M. Black	2000	20
16	Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia Evan A. Stein,D. Roger Illingworth,Peter O. Kwiterovich,Chris A. Liacouras,Martti A. Siimes,Mark Z. Jacobson,Thomas Brewster,Paul N. Hopkins,Michael H. Davidson,Kevin J. Graham,Frederick W. Arensman,Robert H. Knopp,Carlos A. Dujovne,Christine L. Williams,Jonathan L. Isaacsohn,Carol A. Jacobsen,Peter M. Laskarzewski,Sharon Ames,Glenn J. Gormley	1999	196
17	Efficacy and safety of 0.8 mg dosage of cerivastatin, a novel HMG-CoA reductase inhibitor Evan A. Stein,Jonathan L. Isaacsohn,Randall Stoltz,A. Mazzu,M.-C. Liu,C. Lane,Allen H. Heller	1998	7
18	Long-Term Effects of Low-Density Lipoprotein Apheresis Using an Automated Dextran Sulfate Cellulose Adsorption System fn1fn1This study was supported by a grant from the Kaneka America Corporation, New York, New York. Bruce R. Gordon,Sheryl F. Kelsey,Peter C. Dau,Antonio M. Gotto,Kevin J. Graham,D. Roger Illingworth,Jonathan L. Isaacsohn,Peter H. Jones,Susan F. Leitman,Stuart D. Saal,Evan A. Stein,Thomas N. Stern,August J. Troendle,Robert J. Zwiener	1998	82
19	Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels Jonathan L. Isaacsohn,John F. Setaro,Caroline Nicholas,Janice A. Davey,Linda J. Diotalevi,D. Christianson,Ellen Liskov,Evan A. Stein,H BLACK	1994	50
20	A Comparison of the Safety of Therapeutically Equivalent Doses of Isradipine and Diltiazem for Treatment of Essential Hypertension: An Alternative Viewpoint Henry R. Black,Andrew Lewin,Gerald H. Stein,E. Paul MacCarthy,Jennifer Hamilton,B P Hamilton,Nicolaos E. Madias,Mahendr S. Kochar,A. P. Abrams,Jonathan L. Isaacsohn,Mary Ellen Gibbons,K Matthews	1992	5

About Jonathan L. Isaacsohn

Jonathan L. Isaacsohn is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cancer Research, having authored 50 papers that have together received 2.4k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (36 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (16 papers), Cancer, Lipids, and Metabolism (11 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers), Pharmaceutical Economics and Policy (7 papers), Fatty Acid Research and Health (5 papers), Drug Transport and Resistance Mechanisms (2 papers) and Cardiac Imaging and Diagnostics (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (725 citations), Surgery (1.5k citations) and Cardiology and Cardiovascular Medicine (582 citations). Jonathan L. Isaacsohn has collaborated with scholars based in United States, Switzerland and Netherlands. Frequent co-authors include John J.P. Kastelein, Harold Bays, Christie M. Ballantyne, Paresh N. Soni, Rene A. Braeckman, Evan A. Stein, Lawrence Brass, C.D. Robinette, Kathleen R. Merikangas and Evan A. Stein.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact